The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.
Small molecules targeting the innate immune cGAS‒STING‒TBK1 signaling pathway
Open accessAbstract
Multiple cancer immunotherapies including chimeric antigen receptor T cell and immune checkpoint inhibitors (ICIs) have been successfully developed to treat various cancers by motivating the adaptive anti-tumor immunity. Particularly, the checkpoint blockade approach has achieved great clinic success as evidenced by several U.S. Food and Drug Administration (FDA)-approved anti-programmed death receptor 1/ligand 1 or anti-cytotoxic T lymphocyte associated protein 4 antibodies. However, the majority of cancers have low clinical response rates to these ICIs due to poor tumor immunogenicity. Indeed, the cyclic guanosine monophosphate-adenosine monophosphate synthase‒stimulator of interferon genes‒TANK-binding kinase 1 (cGAS‒STING‒TBK1) axis is now appreciated as the major signaling pathway in innate immune response across different species. Aberrant signaling of this pathway has been closely linked to multiple diseases, including auto-inflammation, virus infection and cancers. In this perspective, we provide an updated review on the latest progress on the development of small molecule modulators targeting the cGAS‒STING‒TBK1 signaling pathway and their preclinical and clinical use as a new immune stimulatory therapy. Meanwhile, highlights on the clinical candidates, limitations and challenges, as well as future directions in this field are also discussed. Further, small molecule inhibitors targeting this signaling axis and their potential therapeutic use for various indications are discussed as well.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Pattern Recognition Receptors and Inflammation
Takeuchi, O., & Akira, S. (2010) · Cell · doi:10.1016/j.cell.2010.01.022 · Cited by 8,895
The Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway
Sun, L., Wu, J., Du, F., Chen, X., & Chen, Z. J. (2013) · Science · doi:10.1126/science.1232458 · Cited by 4,996
STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling
Ishikawa, H., & Barber, G. N. (2008) · Nature · doi:10.1038/nature07317 · Cited by 3,576
STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity
Ishikawa, H., Ma, Z., & Barber, G. N. (2009) · Nature · doi:10.1038/nature08476 · Cited by 2,759
Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.-D., Mauceri, H., Beckett, M., Darga, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.019 · Cited by 2,182
Immune checkpoint inhibitors: recent progress and potential biomarkers
Darvin, P., Toor, S. M., Sasidharan Nair, V., & Elkord, E. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0191-1 · Cited by 2,035
Corrales, L., Glickman, L. H., McWhirter, S. M., Kanne, D. B., Sivick, K. E., Katibah, G. E., Woo, S.-R., Lemmens, E., Banda, T., Leong, J. J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.031 · Cited by 1,560
DNA sensing by the cGAS–STING pathway in health and disease
Motwani, M., Pesiridis, S., & Fitzgerald, K. A. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0151-1 · Cited by 1,467
STING: infection, inflammation and cancer.
Barber, G. N. (2015) · Nature Reviews Immunology · doi:10.1038/nri3921 · Cited by 1,313
Gong, J., Chehrazi-Raffle, A., Reddi, S., & Salgia, R. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0316-z · Cited by 1,273
Hargadon, K. M., Johnson, C. E., & Williams, C. J. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.06.001 · Cited by 1,211
Targeting STING with covalent small-molecule inhibitors
Haag, S. M., Gulen, M. F., Reymond, L., Gibelin, A., Abrami, L., Decout, A., Heymann, M., van der Goot, F. G., Turcatti, G., Behrendt, R., et al. (2018) · Nature · doi:10.1038/s41586-018-0287-8 · Cited by 1,178
Gao, P., Ascano, M., Wu, Y., Barchet, W., Gaffney, B. L., Zillinger, T., Serganov, A. A., Liu, Y., Jones, R. A., Hartmann, G., et al. (2013) · Cell · doi:10.1016/j.cell.2013.04.046 · Cited by 1,101
Structural basis of STING binding with and phosphorylation by TBK1
Zhang, C., Shang, G., Gui, X., Zhang, X., Bai, X.-C., & Chen, Z. J. (2019) · Nature · doi:10.1038/s41586-019-1000-2 · Cited by 1,095
cGAS in action: Expanding roles in immunity and inflammation
Ablasser, A., & Chen, Z. J. (2019) · Science · doi:10.1126/science.aat8657 · Cited by 1,077
Zhang, X., Shi, H., Wu, J., Zhang, X., Sun, L., Chen, C., & Chen, Z. J. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.05.022 · Cited by 1,071
Design of amidobenzimidazole STING receptor agonists with systemic activity
Ramanjulu, J. M., Pesiridis, G. S., Yang, J., Concha, N., Singhaus, R., Zhang, S.-Y., Tran, J.-L., Moore, P., Lehmann, S., Eberl, H. C., et al. (2018) · Nature · doi:10.1038/s41586-018-0705-y · Cited by 912
Structural mechanism of cytosolic DNA sensing by cGAS
Civril, F., Deimling, T., de Oliveira Mann, C. C., Ablasser, A., Moldt, M., Witte, G., Hornung, V., & Hopfner, K.-P. (2013) · Nature · doi:10.1038/nature12305 · Cited by 884
Cryo-EM structures of STING reveal its mechanism of activation by cyclic GMP–AMP
Shang, G., Zhang, C., Chen, Z. J., Bai, X.-C., & Zhang, X. (2019) · Nature · doi:10.1038/s41586-019-0998-5 · Cited by 757
Gao, P., Ascano, M., Zillinger, T., Wang, W., Dai, P., Serganov, A. A., Gaffney, B. L., Shuman, S., Jones, R. A., Deng, L., et al. (2013) · Cell · doi:10.1016/j.cell.2013.07.023 · Cited by 582
Advances in cancer immunotherapy 2019 – latest trends
Kruger, S., Ilmer, M., Kobold, S., Cadilha, B. L., Endres, S., Ormanns, S., Schuebbe, G., Renz, B. W., D’Haese, J. G., Schloesser, H., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1266-0 · Cited by 563
Hydrolysis of 2′3′-cGAMP by ENPP1 and design of nonhydrolyzable analogs
Li, L., Yin, Q., Kuss, P., Maliga, Z., Millán, J. L., Wu, H., & Mitchison, T. J. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1661 · Cited by 533
cGAS senses long and HMGB/TFAM-bound U-turn DNA by forming protein-DNA ladders
Andreeva, L., Hiller, B., Kostrewa, D., Lässig, C., de Oliveira Mann, C. C., Jan Drexler, D., Maiser, A., Gaidt, M., Leonhardt, H., Hornung, V., et al. (2017) · Nature · doi:10.1038/nature23890 · Cited by 511
STING and the innate immune response to nucleic acids in the cytosol
Burdette, D. L., & Vance, R. E. (2013) · Nature Immunology · doi:10.1038/ni.2491 · Cited by 501
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non–T-Cell–Inflamed Tumor Microenvironment
Gajewski, T. F. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.011 · Cited by 488
The host STING pathway at the interface of cancer and immunity
Corrales, L., McWhirter, S. M., Dubensky, T. W., & Gajewski, T. F. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86892 · Cited by 487
Big opportunities for small molecules in immuno-oncology
Adams, J. L., Smothers, J., Srinivasan, R., & Hoos, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4596 · Cited by 471
A conserved PLPLRT/SD motif of STING mediates the recruitment and activation of TBK1
Zhao, B., Du, F., Xu, P., Shu, C., Sankaran, B., Bell, S. L., Liu, M., Lei, Y., Gao, X., Fu, X., et al. (2019) · Nature · doi:10.1038/s41586-019-1228-x · Cited by 447
Cancer immunotherapy – revisited
Lesterhuis, W. J., Haanen, J. B. A. G., & Punt, C. J. A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3500 · Cited by 427
Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy
Li, A., Yi, M., Qin, S., Song, Y., Chu, Q., & Wu, K. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0721-x · Cited by 413
STING Polymer Structure Reveals Mechanisms for Activation, Hyperactivation, and Inhibition
Ergun, S. L., Fernandez, D., Weiss, T. M., & Li, L. (2019) · Cell · doi:10.1016/j.cell.2019.05.036 · Cited by 401
Clark, K., Plater, L., Peggie, M., & Cohen, P. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.000414 · Cited by 385
The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors
Tang, J., Yu, J. X., Hubbard-Lucey, V. M., Neftelinov, S. T., Hodge, J. P., & Lin, Y. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.210 · Cited by 382
Vincent, J., Adura, C., Gao, P., Luz, A., Lama, L., Asano, Y., Okamoto, R., Imaeda, T., Aida, J., Rothamel, K., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00833-9 · Cited by 370
The promise and challenges of immune agonist antibody development in cancer
Mayes, P. A., Hance, K. W., & Hoos, A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.75 · Cited by 355
Current status and future directions of cancer immunotherapy
Zhang, H., & Chen, J. (2018) · Journal of Cancer · doi:10.7150/jca.24577 · Cited by 345
STING-dependent cytosolic DNA sensing pathways
Barber, G. N. (2014) · Trends in Immunology · doi:10.1016/j.it.2013.10.010 · Cited by 336
Migrating into the tumor: a roadmap for T cells
van der Woude, L. L., Gorris, M. A. J., Halilovic, A., Figdor, C. G., & de Vries, I. J. M. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.09.006 · Cited by 307
Lama, L., Adura, C., Xie, W., Tomita, D., Kamei, T., Kuryavyi, V., Gogakos, T., Steinberg, J. I., Miller, M., Ramos-Espiritu, L., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08620-4 · Cited by 303
The Cyclopeptide Astin C Specifically Inhibits the Innate Immune CDN Sensor STING
Li, S., Hong, Z., Wang, Z., Li, F., Mei, J., Huang, L., Lou, X., Zhao, S., Song, L., Chen, W., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.097 · Cited by 267
Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity
Fu, Y., Lin, Q., Zhang, Z., & Zhang, L. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.08.010 · Cited by 260
Second- and third-generation drugs for immuno-oncology treatment—The more the better?
Dempke, W. C. M., Fenchel, K., Uciechowski, P., & Dale, S. P. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.001 · Cited by 257
Crew, A. P., Raina, K., Dong, H., Qian, Y., Wang, J., Vigil, D., Serebrenik, Y. V., Hamman, B. D., Morgan, A., Ferraro, C., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00635 · Cited by 257
Cyclic GMP–AMP as an Endogenous Second Messenger in Innate Immune Signaling by Cytosolic DNA
Kato, K., Omura, H., Ishitani, R., & Nureki, O. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-044813 · Cited by 255
Antitumor Activity of cGAMP via Stimulation of cGAS-cGAMP-STING-IRF3 Mediated Innate Immune Response
Li, T., Cheng, H., Yuan, H., Xu, Q., Shu, C., Zhang, Y., Xu, P., Tan, J., Rui, Y., Li, P., et al. (2016) · Scientific Reports · doi:10.1038/srep19049 · Cited by 253
Crystal Structure and Mechanism of Activation of TANK-Binding Kinase 1
Larabi, A., Devos, J. M., Ng, S.-L., Nanao, M. H., Round, A., Maniatis, T., & Panne, D. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.01.034 · Cited by 247
The cGAS-cGAMP-STING Pathway: A Molecular Link Between Immunity and Metabolism
Bai, J., & Liu, F. (2019) · Diabetes · doi:10.2337/dbi18-0052 · Cited by 243
An, J., Woodward, J. J., Sasaki, T., Minie, M., & Elkon, K. B. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402793 · Cited by 239
Crystal structures of STING protein reveal basis for recognition of cyclic di-GMP
Shang, G., Zhu, D., Li, N., Zhang, J., Zhu, C., Lu, D., Liu, C., Yu, Q., Zhao, Y., Xu, S., et al. (2012) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2332 · Cited by 233
cGAS–STING and Cancer: Dichotomous Roles in Tumor Immunity and Development
Ng, K. W., Marshall, E. A., Bell, J. C., & Lam, W. L. (2018) · Trends in Immunology · doi:10.1016/j.it.2017.07.013 · Cited by 218
Prantner, D., Perkins, D. J., Lai, W., Williams, M. S., Sharma, S., Fitzgerald, K. A., & Vogel, S. N. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.382986 · Cited by 216
Species‐specific detection of the antiviral small‐molecule compound CMA by STING
Cavlar, T., Deimling, T., Ablasser, A., Hopfner, K., & Hornung, V. (2013) · The EMBO Journal · doi:10.1038/emboj.2013.86 · Cited by 194
Discovery of a Novel cGAMP Competitive Ligand of the Inactive Form of STING
Siu, T., Altman, M. D., Baltus, G. A., Childers, M., Ellis, J. M., Gunaydin, H., Hatch, H., Ho, T., Jewell, J., Lacey, B. M., et al. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00466 · Cited by 179
Structural insights into cGAMP degradation by Ecto-nucleotide pyrophosphatase phosphodiesterase 1
Kato, K., Nishimasu, H., Oikawa, D., Hirano, S., Hirano, H., Kasuya, G., Ishitani, R., Tokunaga, F., & Nureki, O. (2018) · Nature Communications · doi:10.1038/s41467-018-06922-7 · Cited by 176
Development of immune checkpoint therapy for cancer
Fritz, J. M., & Lenardo, M. J. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20182395 · Cited by 175
Hall, J., Brault, A., Vincent, F., Weng, S., Wang, H., Dumlao, D., Aulabaugh, A., Aivazian, D., Castro, D., Chen, M., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0184843 · Cited by 167
Sondak, V. K., Smalley, K. S. M., Kudchadkar, R. R., Grippon, S., & Kirkpatrick, P. N. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3463 · Cited by 158
Small Molecules Drive Big Improvements in Immuno‐Oncology Therapies
Huck, B. R., Kötzner, L., & Urbahns, K. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201707816 · Cited by 154
Suramin Potently Inhibits cGAMP Synthase, cGAS, in THP1 Cells to Modulate IFN-β Levels
Wang, M., Sooreshjani, M. A., Mikek, C. G., Opoku‐Temeng, C., & Sintim, H. O. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0322 · Cited by 152
TMEM173 variants and potential importance to human biology and disease
Patel, S., & Jin, L. (2018) · Genes and Immunity · doi:10.1038/s41435-018-0029-9 · Cited by 150
An, J., Woodward, J. J., Lai, W., Minie, M., Sun, X., Tanaka, L., Snyder, J. M., Sasaki, T., & Elkon, K. B. (2018) · Arthritis & Rheumatology · doi:10.1002/art.40559 · Cited by 136
Clark, K., Takeuchi, O., Akira, S., & Cohen, P. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1114194108 · Cited by 135
Li, Z., Song, W., Rubinstein, M. P., & Liu, D. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0684-3 · Cited by 131
The Next Generation of Immunotherapy for Cancer: Small Molecules Could Make Big Waves
Kerr, W. G., & Chisholm, J. D. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1800991 · Cited by 131
Lioux, T., Mauny, M.-A., Lamoureux, A., Nicolas, B., Hays, M., Vernejoul, F., Baudru, A.-S., Boularan, C., Lopes-Vicente, J., Qushair, G., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01300 · Cited by 126
Sali, T. M., Pryke, K. M., Abraham, J., Liu, A., Archer, I., Broeckel, R. M., Staverosky, J. A., Smith, J. L., Al-Shammari, A. M., Amsler, L., et al. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1005324 · Cited by 125
Putting the Immunologic Brakes on Cancer
Wolchok, J. D. (2018) · Cell · doi:10.1016/j.cell.2018.11.006 · Cited by 123
Cancer Immunotherapy: Selected Targets and Small‐Molecule Modulators
Weinmann, H. (2016) · ChemMedChem · doi:10.1002/cmdc.201500566 · Cited by 122
Pharmacological Modulation of the STING Pathway for Cancer Immunotherapy
Berger, G., Marloye, M., & Lawler, S. E. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.02.007 · Cited by 117
Gao, P., Zillinger, T., Wang, W., Ascano, M., Dai, P., Hartmann, G., Tuschl, T., Deng, L., Barchet, W., & Patel, D. J. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.08.010 · Cited by 106
Discovery of GSK8612, a Highly Selective and Potent TBK1 Inhibitor
Thomson, D. W., Poeckel, D., Zinn, N., Rau, C., Strohmer, K., Wagner, A. J., Graves, A. P., Perrin, J., Bantscheff, M., Duempelfeld, B., et al. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00027 · Cited by 103
Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy
Torphy, R. J., Schulick, R. D., & Zhu, Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122642 · Cited by 101
Recent advances in small molecule based cancer immunotherapy
Cheng, B., Yuan, W., Su, J., Liu, Y., & Chen, J. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.08.028 · Cited by 101
The evolving landscape of ‘next-generation’ immune checkpoint inhibitors: A review
Mazzarella, L., Duso, B. A., Trapani, D., Belli, C., D’Amico, P., Ferraro, E., Viale, G., & Curigliano, G. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.04.035 · Cited by 101
Identification of α‐Mangostin as an Agonist of Human STING
Zhang, Y., Sun, Z., Pei, J., Luo, Q., Zeng, X. Y., Li, Q., Yang, Z., & Quan, J. (2018) · ChemMedChem · doi:10.1002/cmdc.201800481 · Cited by 92
Small-Molecule Immuno-Oncology Therapy: Advances, Challenges and New Directions
Chen, S., Song, Z., & Zhang, A. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190308131805 · Cited by 81
Self-citationAn RNA-Based Fluorescent Biosensor for High-Throughput Analysis of the cGAS-cGAMP-STING Pathway
Bose, D., Su, Y., Marcus, A., Raulet, D. H., & Hammond, M. C. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2016.10.014 · Cited by 76
A cell-based high throughput screening assay for the discovery of cGAS-STING pathway agonists
Liu, B., Tang, L., Zhang, X., Ma, J., Sehgal, M., Cheng, J., Zhang, X., Zhou, Y., Du, Y., Kulp, J. L., et al. (2017) · Antiviral Research · doi:10.1016/j.antiviral.2017.10.001 · Cited by 74
Rationale for stimulator of interferon genes–targeted cancer immunotherapy
Vargas, T. R., Benoit-Lizon, I., & Apétoh, L. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.028 · Cited by 67
Small-Molecule Targets in Immuno-Oncology
Dhanak, D., Edwards, J. P., Nguyen, A., & Tummino, P. J. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.08.019 · Cited by 67
Drug developers switch gears to inhibit STING
Sheridan, C. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0060-z · Cited by 62
Discovery and Mechanistic Study of a Novel Human-Stimulator-of-Interferon-Genes Agonist
Zhang, X., Liu, B., Tang, L., Su, Q., Hwang, N., Sehgal, M., Cheng, J., Ma, J., Zhang, X., Tan, Y., et al. (2019) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00010 · Cited by 62
TANK-binding kinase 1 as a novel therapeutic target for viral diseases
Zhao, C., & Zhao, W. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1601702 · Cited by 61
Salama, A. K. S., & Moschos, S. J. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw534 · Cited by 57
TBK1 inhibitors: a review of patent literature (2011 – 2014)
Yu, T., Yang, Y., Yin, D. Q., Hong, S., Son, Y., Kim, J., & Cho, J. Y. (2015) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2015.1081168 · Cited by 55
Beyett, T. S., Gan, X., Reilly, S. M., Chang, L. C., Gomez, A. V., Saltiel, A. R., Showalter, H. D., & Tesmer, J. J. G. (2018) · Molecular Pharmacology · doi:10.1124/mol.118.112185 · Cited by 51
STING modulators: Predictive significance in drug discovery
Cui, X., Zhang, R., Cen, S., & Zhou, J. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111591 · Cited by 48
Selective TBK1/IKKi dual inhibitors with anticancer potency
Li, J., Huang, J., Jeong, J.-H., Park, S.-J., Wei, R., Peng, J., Luo, Z., Chen, Y., Feng, Y., & Luo, J. (2013) · International Journal of Cancer · doi:10.1002/ijc.28507 · Cited by 42
Hwang, J., Kang, T., Lee, J. H., Choi, B., & Han, S. (2018) · Organic & Biomolecular Chemistry · doi:10.1039/c8ob01798k · Cited by 39
Crystal structure of the ubiquitin-like domain of human TBK1
Li, J., Li, J., Miyahira, A. K., Sun, J. G., Liu, Y., Cheng, G., & Liang, H. (2012) · Protein & Cell · doi:10.1007/s13238-012-2929-1 · Cited by 36
Nivolumab in the treatment of malignant melanoma: review of the literature
Nakamura, M., Mashima, E., Yamaguchi, T., Sasaki, N., Hara, Y., Omoto, D., Haruyama, S., Yoshioka, M., Nishio, D., Sakuragi, Y., et al. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s62102 · Cited by 35
Identification and Further Development of Potent TBK1 Inhibitors
Richters, A., Basu, D., Engel, J., Ercanoglu, M. S., Balke‐Want, H., Tesch, R., Thomas, R. K., & Rauh, D. (2014) · ACS Chemical Biology · doi:10.1021/cb500908d · Cited by 29
A Click‐Chemistry Linked 2′3′‐cGAMP Analogue
Dialer, C. R., Stazzoni, S., Drexler, D. J., Müller, F., Veth, S., Pichler, A., Okamura, H., Witte, G., Hopfner, K., & Carell, T. (2018) · Chemistry - A European Journal · doi:10.1002/chem.201805409 · Cited by 19
O’Donovan, D. H., Mao, Y., & Mele, D. A. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190620103105 · Cited by 19
Tan, M., & Quintal, L. (2015) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12304 · Cited by 14
Lee, S., Gharbi, A., You, J. S., Han, H. D., Kang, T. H., Hong, S. H., Park, W. S., Jung, I. D., & Park, Y. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.05.051 · Cited by 10
Cited by
Cold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 682
Radiotherapy combined with immunotherapy: the dawn of cancer treatment
Zhang, Z., Liu, X., Chen, D., & Yu, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01102-y · Cited by 670
Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy
Garland, K. M., Sheehy, T. L., & Wilson, J. T. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00750 · Cited by 357
Oduro, P. K., Zheng, X., Wei, J., Yang, Y., Wang, Y., Zhang, H., Liu, E., Gao, X., Du, M., & Wang, Q. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.05.011 · Cited by 339
Role of the cGAS–STING pathway in systemic and organ-specific diseases
Skopelja-Gardner, S., An, J., & Elkon, K. B. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00589-6 · Cited by 307
Metadata
- Authors
- Ding, C., Song, Z., Shen, A., Chen, T., & Zhang, A.
- Venue
- Acta Pharmaceutica Sinica B
- Publisher
- Elsevier BV
- Published
- 2020-12
- Volume
- 10
- Issue
- 12
- Pages
- 2272-2298
- ISSN
- 2211-3835 (ISSN-L)
- OpenAlex
- W3011178559
- Cited by
- 306
- References
- 99
- FWCI
- 10.12
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.